J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment, at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco.
Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment.
